p53 antibody | DO-11
No associated image currently available
Mouse anti Human p53 antibody, clone DO-11 recognizes the human Cellular tumor antigen p53, also known as p53 tumour suppressor protein or NY-CO-13. p53 is a 393 amino acid ~53kDa cytoplasmic/ nuclear protein up-regulated in response to DNA damage and is found in a wide variety of transformed cells (UniProt: P04637).
DO-11 binds to an epitope within the central region of p53 between amino acids 181 - 190 defining a cryptic epitope exposed in unfolded/ denatured p53 (Shimitzu et al. 2006). Nine isoforms of human p53 are produced by alternative splicing and promotor usage, the epitope recognized by clone DO-11 is present in all isoforms. Mouse anti Human p53 antibody, clone DO-11 recognizes mutant forms of p53 (Warnock et al. 2011) and has been used successfully for detection of p53 by western blotting (Wei et al. 2012).
DO-11 binds to an epitope within the central region of p53 between amino acids 181 - 190 defining a cryptic epitope exposed in unfolded/ denatured p53 (Shimitzu et al. 2006). Nine isoforms of human p53 are produced by alternative splicing and promotor usage, the epitope recognized by clone DO-11 is present in all isoforms. Mouse anti Human p53 antibody, clone DO-11 recognizes mutant forms of p53 (Warnock et al. 2011) and has been used successfully for detection of p53 by western blotting (Wei et al. 2012).
Product Details
- Target Species
- Human
- Product Form
- Purified IgG - liquid
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
0.09% Sodium Azide - Carrier Free
- Yes
- Immunogen
- Recombinant human p53.
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- Fusion Partners
- Spleen cells from immunised BALB/c mice were fused with cells of the mouse X63Ag8.653 myeloma cell line.
Storage Information
- Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Guarantee
- 18 months from date of despatch.
More Information
- UniProt
- P04637 Related reagents
- Entrez Gene
- TP53 Related reagents
- Regulatory
- For research purposes only
Applications of p53 antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| Immunohistology - Frozen | |||
| Immunohistology - Paraffin 1 | 1/1000 | ||
| Immunoprecipitation | |||
| Western Blotting | 1/1000 |
- 1This product requires antigen retrieval using heat treatment prior to staining of paraffin sections.Sodium citrate buffer pH 6.0 is recommended for this purpose.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
- Histology Positive Control Tissue
- Colon or breast carcinoma
Copyright © 2019 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Product Specific References
References for p53 antibody
-
Vojtěšek, B. et al. (1995) Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein.
Oncogene. 10: 389-393. -
Palecek, E. et al. (2001) Binding of p53 and its core domain to supercoiled DNA.
Eur J Biochem. 268: 573-81. -
Coomber, D.W. and Ward, .R.L. (2001) Isolation of human antibodies against the central DNA binding domain of p53 from an individual with colorectal cancer using antibody phage display.
Clin Cancer Res. 7: 2802-8. -
Wei, J. et al. (2012) Pathogenic bacterium Helicobacter pylori alters the expression profile of p53 protein isoforms and p53 response to cellular stresses.
Proc Natl Acad Sci U S A. 109: E2543-50. -
Warnock, L.J. et al. (2011) Aurora A mediates cross-talk between N- and C-terminal post-translational modifications of p53.
Cancer Biol Ther. 12: 1059-68.
